Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000666488 | SCV000790792 | uncertain significance | Alstrom syndrome | 2017-04-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000666488 | SCV001236802 | uncertain significance | Alstrom syndrome | 2022-08-16 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 2027 of the ALMS1 protein (p.Lys2027Glu). This variant is present in population databases (rs191286546, gnomAD 0.009%). This variant has not been reported in the literature in individuals affected with ALMS1-related conditions. ClinVar contains an entry for this variant (Variation ID: 551430). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome- |
RCV000666488 | SCV001781466 | uncertain significance | Alstrom syndrome | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000666488 | SCV002775138 | uncertain significance | Alstrom syndrome | 2022-03-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004026092 | SCV005026787 | likely benign | Cardiovascular phenotype | 2023-11-13 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV004597854 | SCV005093351 | uncertain significance | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | ALMS1: PM2, BP4 |
Natera, |
RCV000666488 | SCV002082819 | uncertain significance | Alstrom syndrome | 2021-06-07 | no assertion criteria provided | clinical testing |